Anthropic detailed six life-sciences partnerships and acquired Mithril Medicine as it begins internal drug-discovery programs using Claude.
Anthropic says it is expanding its work in drug development through research partnerships with six organizations and the acquisition of Mithril Medicine, a one-person company pursuing treatments for two rare forms of muscular dystrophy. The October 27 announcement marks a move beyond supplying AI tools to outside researchers: Anthropic says it has started its own drug-discovery programs, with Mithril founder Cody Tranbarger continuing the work after joining the company.
The company described projects spanning different stages of development. At Generate Biomedicines, researchers used Claude Code to propose a shortened genetic instruction for a potential CAR T-cell therapy. In laboratory tests, the design helped immune cells produce more receptors and kill tumor cells more efficiently. At Divergence Labs, Claude generated roughly 35,000 antibody designs for a proposed food-allergy treatment; early tests identified candidate designs for further work. Anthropic also reported that Enveda used Claude to review manufacturing documentation and draft regulatory materials, while Bristol Myers Squibb is testing the model for clinical-trial planning.
Anthropic said Mithril used Claude to coordinate contracts, logistics and experiments with 11 external laboratories. The company reports that one possible treatment advanced from an idea to promising results in mice in less than 18 months. Anthropic says a drug candidate could be ready to begin human clinical trials as soon as late 2028 if the research continues to hold up. These are company-reported, early-stage findings—not evidence of an approved or proven treatment.
The broader strategy is to involve Claude across the drug-development process, from identifying targets and designing molecules to manufacturing, regulatory filings and clinical trials. Anthropic argues that bottlenecks occur throughout this chain, so working directly with drug programs can reveal where models help and where they need improvement. It says the partnerships have already informed plans to improve Claude, and that it intends to scale the work.
Most of the research remains preclinical, and Anthropic acknowledges that substantial testing and development lie ahead. The company says it also aims to share its models with researchers through Claude Science, credits for life scientists and a verification program for trusted organizations. The announcement signals a deeper life-sciences push, while leaving the therapeutic impact dependent on future validation.